Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 48, Issue 12, 2007, Pages 2352-2359

  Shimoni, Avichai ^a   Hardan, Izhar ^a   Shem Tov, Noga ^a   Rand, Avital ^a   Yerushalmi, Ronit ^a   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Acute myeloid leukemia; Reduced intensity conditioning; Stem cell transplantation; Treosulfan

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN A; FLUDARABINE; FRESENIUS; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NARCOTIC AGENT; THYMOCYTE ANTIBODY; TREOSULFAN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; METABOLIC ACIDOSIS; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PNEUMOCYSTOSIS; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; AGED; BUSULFAN; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 37149000672     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701671051     Document Type: Article

References (27)

1. Champlin, R., Khouri, I., Shimoni, A., Gajewski, J., Kornblau, S. and Molldrem, J. (2000) Harnessing graft-versus-malignancy: Nonmyeloablative preparative regimens for allogeneic haematopoietic transplantation. An evolving strategy for adoptive immunotherapy. Br J Haematol, 11, pp. 18-29.
2. Shimoni, A. and Nagler, A. (2004) Nonmyeloablative stem cell transplantation: Lessons from the first decade of clinical experience. Curr Hematol Rep, 3, pp. 242-248.
3. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M. and Cividalli, G. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood, 91, pp. 756-763.
4. Shimoni, A., Hardan, I., Shem-Tov, N., Yeshurun, M., Yerushalmi, R. and Avigdor, A. (2006) Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia, 20, pp. 322-328.
5. Hartley, J. A., O'Hare, C. C. and Baumgart, J. (1999) DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer, 79, pp. 264-266.
6. Gropp, M., Meier, W. and Hepp, H. (1998) Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol, 71, pp. 94-98.
7. Schmidmaier, R., Oellerich, M., Baumgart, J., Emmerich, B. and Meinhardt, G. (2004) Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. Exp Hematol, 32, pp. 76-86.
8. Fichtner, I., Becker, M. and Baumgart, J. (2003) Antileukaemic activety of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer, 39, pp. 801-807.
9. Koenigsmann, M., Mohren, M., Jentsch-Ullrich, K., Franke, A., Becker, E. and Heim, M. (2004) High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant, 34, pp. 477-483.
10. Meinhardt, G., Dayyani, F., Jahrsdorfer, B., Baumgart, J., Emmerich, B. and Schmidmaier, R. (2003) Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol, 122, pp. 892-899.
11. Ploemacher, R. E., Johnson, K. W., Rombouts, E. J., Etienne, K., Westerhof, G. R. and Baumgart, J. (2004) Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant, 10, pp. 236-245.
12. Westerhof, G. R., Ploemacher, R. E., Boudewijn, A., Blokland, I., Dillingh, J. H. and McGown, T. (2000) Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res, 60, pp. 5470-5478.
13. Sjoo, F., Hassan, Z., Abedi-Valugerdi, M., Griskevicius, L., Nilsson, C. and Remberger, M. (2006) Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol, 34, pp. 115-121.
14. Scheulen, M. E., Hilger, R. A., Oberhoff, C., Casper, J., Freund, M. and Josten, K. M. (2000) Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res, 6, pp. 4209-4216.
15. Casper, J., Knauf, W., Kiefer, T., Wolff, D., Steiner, B. and Hammer, U. (2004) Treosulfan and fludarabine: A new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood, 103, pp. 725-731.
16. Casper, J., Knauf, W., Blau, I., Ruutu, T., Volin, L. and Wandt, H. (2004) Treosulfan/fludarabine: A new conditioning regimen in allogeneic transplantation. Ann Hematol, 83, pp. S70-S71.
17. Beelen, D. W., Trenschel, R., Casper, J., Freund, M., Hilger, R. A. and Scheulen, M. E. (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant, 35, pp. 233-241.
18. Kroger, N., Shimoni, A., Zabelina, T., Schieder, H., Panse, J. and Ayuk, F. (2006) Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant, 37, pp. 339-344.
19. Shimoni, A. and Nagler, A. (2001) Non-myeloablative stem cell transplantation (NST): Chimerism testing as guidance for immune-therapeutic manipulations. Leukemia, 15, pp. 1967-1975.
20. Kaplan, E. L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assos, 53, pp. 457-481.
21. Gooley, T. A., Leisenring, W., Crowley, J. and Storer, B. E. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med, 18, pp. 695-706.
22. Alyea, E. P., Kim, H. T., Ho, V., Cutler, C., Gribben, J. and DeAngelo, D. J. (2005) Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood, 105, pp. 1810-1814.
23. Aoudjhane, M., Labopin, M., Gorin, N. C., Shimoni, A., Ruutu, T. and Kolb, H. J. (2005) Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia, 19, pp. 2304-2312.
24. van Pel, M., van Breugel, D. W., Vos, W., Ploemacher, R. E. and Boog, C. J. (2003) Towards a myeloablative regimen with clinical potential. I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers. Bone Marrow Transplant, 32, pp. 15-22.
25. van Pel, M., van Breugel, D. W., Vos, W., Ploemacher, R. E. and Boog, C. J. (2004) Toward a myeloablative regimen with clinical potential. II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers. Bone Marrow Transplant, 33, pp. 153-159.
26. Antin, J. H. and Ferrara, J. L. (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood, 80, pp. 2964-2968.
27. Shimoni, A., Hardan, I., Shem-Tov, N., Rand, A., Herscovici, C. and Yerushalmi, M. (2007) Comparison between two fludarabine-based reduced-intensity conditioning regimens prior to allogeneic stem cell transplantation: Fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia, 21, pp. 2109-2116.